The trial was actively recruiting participants throughout the United States
Common contraindications cited in the research-use community include: anyone with active or recent cancer (BPC-157 and TB-500 promote angiogenesis), people with Wilson's disease or other copper-metabolism disorders (GHK-Cu component), anyone pregnant or breastfeeding (no safety data), and athletes subject to WADA testing (BPC-157 and TB-500 are prohibited)
Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture
Antioxidant Power Neutralizes free radicals: Helps protect cells from oxidative damage, which can lead to aging, inflammation, and chronic diseases
Frequently Asked Questions Conclusion AOD9604 represents a paradigm shift in weight management, offering a safe, effective, and science-backed alternative to traditional methods
F.van den BroekJ.van TolH